European Bioanalysis Forum recommendation: Scientific validation of quantification by accelerator mass spectrometry

Bioanalysis

Volumn 4, Issue 22, 2012, Pages 2669-2679

  Higton, David ^a   Young, Graeme ^b   Timmerman, Philip ^c   Abbott, Richard ^d   Knutsson, Magnus ^e   Svensson, Leif D ^f  

^a ASTRAZENECA   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

^c JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^d Shire Pharmaceuticals   (United Kingdom)

^e Ferring Pharmaceuticals AS   (Denmark)

^f Active Biotech Research AB   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ACCELERATOR MASS SPECTROMETRY; ACCURACY; ARTICLE; BIOASSAY; CALIBRATION; CLINICAL STUDY; CONTAMINATION; DRUG ELIMINATION; DRUG METABOLISM; EUROPEAN BIOANALYSIS FORUM; EXTRACTION; FRACTIONATION; FREEZE THAWING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INCURRED SAMPLE REPRODUCIBILITY; ISOTOPE LABELING; LIGAND BINDING; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; MEDICAL SOCIETY; PRACTICE GUIDELINE; PURIFICATION; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; SEPARATION TECHNIQUE; TANDEM MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY;

CHROMATOGRAPHY, LIQUID; DRUG DISCOVERY; EUROPE; HUMANS; MASS SPECTROMETRY; PHARMACOKINETICS; VALIDATION STUDIES AS TOPIC;

EID: 84870532212     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.12.242     Document Type: Article

References (20)

1. Dijksman J, Timmerman P, Abbott R et al. 'Less is more': defining modern bioanalysis. Bioanalysis 4(6), 633-642 (2012).
2. US Department of Health and Human Services, US FDA, Center for Drug Evaluation, Center for Veterinary Medicine. Guidance for Industry Bioanalytical Method Validation. Rockville, MD, USA (2001).
3. Viswanathan C, Bansal S, Booth B et al. Fit-for-purpose method development and validation for successful biomarker measurement. Pharm. Res. 23(2), 312-328 (2006).
4. Committee for Medicinal Products for Human Use. European Medicines Agency. Guideline on Bioanalytical Method Validation. London, UK (2011).
5. Lappin G, Seymour M, Young G et al. AMS method validation for quantitation in pharmacokinetic studies with concomitant extravascular and intravenous administration. Bioanalysis 3(4), 393-405 (2011).
6. Timmerman P, Kall MA, Gordon B et al. Best practices in a tiered approach to metabolite quantification: views and recommendations of the European Bioanalysis Forum. Bioanalysis 2(7), 1185-1194 (2010).
7. Barker J, Garner RC. Biomedical applications of accelerator mass spectrometry-isotope measurements at the level of the atom. Rapid Comm. Mass Spectrom. 13(4), 285-293 (1999). (Pubitemid 29101097)
8. Turteltaub KW, Felton JS, Gledhill BL et al. Accelerator mass spectrometry in biomedical dosimetry: relationship between low-level exposure and covalent binding of heterocyclic amine carcinogens to DNA. Proc. Natl Acad. Sci. USA 87(14), 5288-5292 (1990). (Pubitemid 20260164)
9. Creek MR, Mani C, Vogel JS, Turteltaub KW. Tissue distribution and macromolecular binding of extremely low doses of [14C]-benzene in B6C3F1 mice. Carcinogenesis 18(12), 2421-2427 (1997). (Pubitemid 28134658)
10. Young G, Ellis W, Ayrton J, Hussey E, Adamkiewicz B. Accelerator mass spectrometry (AMS): recent experience of its use in a clinical study and potential future of the technique. Xenobiotica 31(8-9), 619-632 (2001). (Pubitemid 32826395)
11. Lappin G, Garner RC. The utility of microdosing over the past 5 years. Expert Opin. Drug Metab. Toxicol. 4(12), 1499-1506 (2008).
12. Lappin G, Kuhnz W, Jochemsen R et al. Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs. Clin. Pharm. Therap. 80(3), 203-215 (2006). (Pubitemid 44313903)
13. Lappin G, Shishikura Y, Jochemsen R et al. Comparative pharmacokinetics between a microdose and therapeutic dose for clarithromycin, sumatriptan, propafenone, paracetamol (acetaminophen), and phenobarbital in human volunteers. Eur. J. Pharm. Sci. 43(3), 141-150 (2011).
14. Miyaji Y, Ishizuka T, Kawai K et al. Use of an intravenous microdose of 14C-labeled drug and accelerator mass spectrometry to measure absolute oral bioavailability in dogs; cross-comparison of assay methods by accelerator mass spectrometry and liquid chromatography-tandem mass spectrometry. Drug Metab. Pharmacokinet. 24(2), 130-138 (2009).
15. Sarapa N, Hsyu P, Lappin G, Garner RC. The application of accelator mass spectrometry to absolute bioavailability studies in humans: simultaneous administration of an intravenous microdose of 14C-nelfinavir mesylate solution and oral nelfinavir to healthy volunteers. J. Clin. Pharmacol. 45(10), 1198-1205 (2005). (Pubitemid 41361920)
16. Strong JM, Dutcher JS, Lee WK, Atkinson AJ Jr. Absolute bioavailability in man of n-acetylprocainamide determined by a novel stable isotope method. Clin. Pharmacol. Ther. 18(5), 613-622 (1975).
17. European Medicines Agency. ICH M3 (R2) Guideline: Guidance on Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals. London, UK (2009).
18. Krumbiegel P. Large deuterium isotope effects and their use: a historical review. Isotopes Environ. Health Stud. 47(1), 1-17 (2011).
19. Nelson S, Trager W. The use of deuterium isotope effects to probe the active site properties, mechanism of cytochrome p450- catalyzed reactions, and mechanisms of metabolically dependent toxicity. Drug. Metab. Dispos. 31(12), 1481-1498 (2003). (Pubitemid 37466917)
20. Lappin G, Seymour M, Young G et al. An AMS method to determine analyte recovery from pharmacokinetic studies with concomitant extravascular and intravenous administration. Bioanalysis 3(4), 407-410 (2011).